Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Revance Therapeutics	Madrigal Pharmaceuticals	Harmony Biosciences	Generation Bio	Stoke Therapeutics
Symbol	NASDAQ:RVNC	NASDAQ:MDGL	NASDAQ:HRMY	NASDAQ:GBIO	NASDAQ:STOK
Price Information
Current Price	$27.22	$124.77	$28.15	$28.30	$30.91
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.7	1.7	1.4	1.8	1.4
Analysis Score	3.5	3.4	3.5	3.5	3.4
Community Score	2.6	2.8	2.1	3.8	3.0
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	2.5	0.8	0.8	0.8
Earnings & Valuation Score	0.6	0.0	0.6	0.6	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$37.75	$167.60	$51.67	$40.60	$64.33
% Upside from Price Target	38.68% upside	34.33% upside	83.54% upside	43.46% upside	108.13% upside
Trade Information
Market Cap	$1.94 billion	$2.00 billion	$1.60 billion	$1.60 billion	$1.13 billion
Beta	1.42	1.19	N/A	N/A	0.63
Average Volume	442,049	180,346	126,336	683,567	165,817
Sales & Book Value
Annual Revenue	$410,000.00	N/A	N/A	N/A	N/A
Price / Sales	4,739.13	N/A	N/A	N/A	N/A
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$5.00 per share	$27.00 per share	N/A	N/A	$6.86 per share
Price / Book	5.44	N/A	N/A	N/A	N/A
Profitability
Net Income	$-159,430,000.00	$-83,950,000.00	N/A	N/A	$-32,330,000.00
EPS	($3.67)	($5.45)	N/A	N/A	($1.80)
Trailing P/E Ratio	N/A	N/A	0.00	0.00	N/A
Forward P/E Ratio	N/A	N/A	24.27	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-5,818.87%	N/A	N/A	N/A	N/A
Return on Equity (ROE)	-85.72%	-47.64%	N/A	N/A	-22.93%
Return on Assets (ROA)	-44.85%	-43.21%	N/A	N/A	-22.26%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.48%	N/A	2.04%	N/A	N/A
Current Ratio	7.07%	6.84%	7.87%	31.19%	29.02%
Quick Ratio	7.01%	6.84%	7.80%	31.19%	29.02%
Ownership Information
Institutional Ownership Percentage	74.35%	74.24%	50.17%	63.26%	N/A
Insider Ownership Percentage	4.80%	41.89%	N/A	N/A	54.60%
Miscellaneous
Employees	470	29	150	100	56
Shares Outstanding	71.38 million	16.03 million	56.89 million	56.43 million	36.66 million
Next Earnings Date	5/6/2021 (Estimated)	5/6/2021 (Estimated)	6/24/2021 (Estimated)	6/17/2021 (Estimated)	5/21/2021 (Estimated)
Optionable	Optionable	Optionable	Not Optionable	Not Optionable	Not Optionable

Source	Headline
	Stoke Therapeutics (NASDAQ:STOK) Shares Gap Down to $34.35 americanbankingnews.com - April 12 at 12:36 PM
	Birmingham City team news vs Stoke - Bowyer makes two changes and calls-up teen star birminghammail.co.uk - April 10 at 1:59 PM
	Birmingham v Stoke City live - Action from St Andrew's stokesentinel.co.uk - April 10 at 1:59 PM
	U18s match report: United 6 Stoke 1 manutd.com - April 10 at 1:59 PM
	Birmingham City 2-0 Stoke City: Lukas Jutkiewicz double sees off Potters bbc.com - April 10 at 1:59 PM
	Birmingham 2-0 Stoke City: Lukas Jutkiewicz double fires Blues closer to safety skysports.com - April 10 at 1:59 PM
	Michael O'Neill wants throw-in rule change after Stoke City put on other foot at Birmingham stokesentinel.co.uk - April 10 at 1:59 PM
	Oversold Conditions For Stoke Therapeutics (STOK) nasdaq.com - April 6 at 5:47 PM
	Stoke Therapeutics Announces MHRA Authorization to Initiate Phase 1/2a Clinical Trial of STK-001 for Dravet Syndrome in the United Kingdom finance.yahoo.com - March 30 at 7:58 AM
	Stoke Therapeutics (NASDAQ:STOK) Shares Down 3.6% americanbankingnews.com - March 26 at 12:05 PM
	Stoke Therapeutics (NASDAQ:STOK) Sees Strong Trading Volume americanbankingnews.com - March 25 at 11:19 AM
	Stoke Therapeutics to Present at Upcoming Investor Conferences finance.yahoo.com - March 24 at 7:58 AM
	We're Not Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn finance.yahoo.com - March 15 at 4:37 PM
	Stoke Therapeutics Reports Full Year 2020 Financial Results and Provides Business Updates finance.yahoo.com - March 9 at 8:20 AM
	MRSN Mar 2021 17.500 put uk.finance.yahoo.com - March 8 at 9:40 AM
	Stoke Therapeutics Inc (STOK) CFO Stephen J Tulipano Sold $1.8 million of Shares finance.yahoo.com - February 24 at 8:46 PM
	Mersana Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference finance.yahoo.com - January 6 at 9:19 AM
	Mersana Therapeutics Announces Corporate and Pipeline Updates and 2021 Goals and Anticipated Milestones finance.yahoo.com - January 5 at 1:13 PM
	MRSN May 2021 17.500 put uk.finance.yahoo.com - January 1 at 3:35 AM
	MRSN Jan 2021 12.500 put uk.finance.yahoo.com - December 31 at 10:08 PM
	MRSN Jan 2021 22.500 put uk.finance.yahoo.com - December 31 at 10:08 PM
	STOK Jan 2021 50.000 put au.finance.yahoo.com - December 29 at 12:38 AM
	STOK Feb 2021 65.000 call au.finance.yahoo.com - December 28 at 2:33 PM
	STOK Jan 2021 30.000 call au.finance.yahoo.com - December 27 at 10:16 PM
	STOK Feb 2021 20.000 call au.finance.yahoo.com - December 27 at 10:16 PM

Date	Company	Brokerage	Action
4/14/2021	Revance Therapeutics	Needham & Company LLC	Reiterated Rating
3/1/2021	Revance Therapeutics	HC Wainwright	Boost Price Target
2/23/2021	Revance Therapeutics	Mizuho	Boost Price Target
10/26/2020	Revance Therapeutics	Barclays	Boost Price Target
4/16/2020	Revance Therapeutics	Stifel Nicolaus	Lower Price Target
3/27/2020	Revance Therapeutics	William Blair	Reiterated Rating
3/22/2020	Revance Therapeutics	The Goldman Sachs Group	Downgrade
2/25/2020	Revance Therapeutics	Piper Sandler	Boost Price Target
3/4/2021	Madrigal Pharmaceuticals	Chardan Capital	Boost Price Target
3/2/2021	Madrigal Pharmaceuticals	Oppenheimer	Lower Price Target
11/23/2020	Madrigal Pharmaceuticals	Evercore ISI	Reiterated Rating
11/12/2020	Madrigal Pharmaceuticals	Canaccord Genuity	Lower Price Target
11/6/2020	Madrigal Pharmaceuticals	BMO Capital Markets	Boost Price Target
5/22/2020	Madrigal Pharmaceuticals	B. Riley	Boost Price Target
3/5/2020	Madrigal Pharmaceuticals	Citigroup	Lower Price Target
9/14/2020	Harmony Biosciences	Jefferies Financial Group	Initiated Coverage
3/22/2021	Generation Bio	JPMorgan Chase & Co.	Boost Price Target
7/7/2020	Generation Bio	Wedbush	Initiated Coverage
7/7/2020	Generation Bio	Cowen	Initiated Coverage
3/16/2021	Stoke Therapeutics	Credit Suisse Group	Boost Price Target
11/13/2020	Stoke Therapeutics	BTIG Research	Boost Price Target
10/23/2020	Stoke Therapeutics	Cantor Fitzgerald	Initiated Coverage

(Data available from 4/19/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources